newsfilter
← Latest News
GlobeNewswire·

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Study met primary endpoint demonstrating barzolvolimab's ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes providing direct